25 preclinical studies, 18 months, 1 out licensed compound With the number of blockbuster drugs approaching patent expiration and pharma companies struggling to maintain pipeline and portfolios with in-house programs, companies are increasingly turning to licensing, aquisitions and partnerships. Early-stage licensing deals tend to carry more risk for pharma companies..
Read more
C57Bl/6 is a common background for generating genetically modified strains for use in in vivo models of arthritis. While these strains are commonly used, they are also known for requiring larger amounts of induction reagents, present with lower incidence rates and often times a milder disease course. In the..
Read more
K/BxN mice spontaneously develop a severe, chronic, progressive inflammatory arthritis at about 27 days of age. They develop auto-antibodies recognizing glucose-6-phosphate isomerase. Serum from these animals when transferred to recipient animals induce arthritis. The mechanism of action involves complement, mast cells, neutrophils and inflammatory mediators. This model is widely used for..
Read more